tldrdailynews.com logo

FDA Delays Decision on Eli Lilly's Alzheimer's Drug Donanemab

1 min read
Source: Financial Times
TL;DR

The US regulator has postponed its decision on Eli Lilly's experimental Alzheimer's drug, donanemab, citing the need for more time to review additional data. The drug has shown promise in slowing the progression of the disease, and the delay in the decision is seen as a setback for the company's efforts to bring a new treatment to market.

Topics:businesshealthcare#alzheimers-drug#decision-delay#donanemab#eli-lilly#healthcare#us-regulator
Share this article
  1. US regulator delays decision on Eli Lilly's Alzheimer's drug donanemab  Financial Times
  2. U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab | Eli Lilly and Company  Investors | Eli Lilly and Company
  3. F.D.A. Delays Action on Closely Watched Alzheimer's Drug  The New York Times
  4. Eli Lilly's donanemab Alzheimer's drug delayed by FDA  USA TODAY
  5. Eli Lilly hits another Alzheimer's hurdle. But obesity, diabetes GLP-1s strong  CNBC

Want the full story? Read the original reporting

Read on Financial Times